Pfizer easily beat Wall Street expectations as the biggest U.S. drugmaker's first-quarter net income jumped 27% due to higher sales, a lower tax bill and some one-time gains. The company raised its 2016 financial forecasts, citing the strong quarter and an improved business outlook.
Concerns over the threat hackers pose to medical devices were the basis for draft guidance issued Friday by the U.S. Food and Drug Administration that would call on manufacturers to report to the agency cybersecurity vulnerabilities that endanger patient safety.
Pfizer's $160 billion deal to acquire Irish drugmaker Allergan got a lot of attention for the tax advantages Pfizer would enjoy from moving its New Jersey headquarters overseas to Dublin. There wasn't much talk, though, about how much the deal would expand Pfizer's footprint in biosimilars.
Drugmaker Pfizer says it has completed its roughly $15 billion purchase of the injectable-drug maker and infusion-device manufacturer Hospira, expanding its product offerings in a growing medical market.
Drugmaker Pfizer says it's received the final regulatory approvals for its $15.23 billion purchase of the injectable drug and infusion devicemaker Hospira, and says the deal will close in early September. The FTC has ordered Pfizer to sell four drugs in order to preserve competition.
The federal government says healthcare facilities should stop using Hospira's Symbiq medication infusion pump because of its vulnerability to hacking.
The Food and Drug Administration is reporting shortages of pre-filled syringes of epinephrine, which are most commonly used to treat individuals who are in cardiac arrest.
Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer, Merck & Co. and Bristol-Myers Squibb Co., which reported first-quarter results Tuesday, all derive at least half their...
Federal regulators have approved the first biosimilar drug to be sold in the U.S., a move that could lower treatment costs as biosimilars compete with what historically had been more expensive medications.
Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the patents protecting the company's top-selling antibiotic just hours after that deal was announced Monday.
Drugmaker Hospira said Wednesday that it received a warning letter from the Food and Drug Administration regarding poor manufacturing quality at one of its facilities in Australia.
Pharmaceutical and medical-device maker Hospira saw its earnings soar in the second quarter of 2014, thanks mostly to large sales of drugs that have been in short supply.